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The particle size of droplet, viscosity, physical properties of interface and 
critical micelle concentration could affect the formulation of a stabile non-
aqueous emulsion. However, with the attractive features of a non-aqueous 
emulsion system, a challenge remains for thermodynamically stable non-
aqueous emulsions for further development to be applied in the 
pharmaceutical field. Non-aqueous emulsions have been used for oral and 
topical drug delivery, protein and peptide drug delivery, periodontal pocket 
delivery, controlled drug delivery and cosmetic application. These systems 
also have been filled in capsule or used as carrier for magnetite 
nanoparticles and prepared as the multiple emulsion. 






Although there are limited applications in the 
pharmaceutical field, the non-aqueous emulsion system could 
be applied in topical drug delivery system1 to prepare the 
nano– and micro- particles2, as a parenteral drug delivery 
system itself3,4 or in non-aqueous in situ forming microparticle 
( ISM)  systems.5 Non- aqueous emulsions may be used 
advantageously in pharmaceutical and cosmetic applications 
if they are composed primarily of edible, non-toxic ingredients 
and can be formulated to exhibit a wide range of suitable 
properties.  Some possible usages includes the topical 
application bases for dermatological formulations, particularly 
for poorly- stable drugs or as emollient bases for various 
cosmetic preparations; for example, deodorants, skin cream, 
hair care products.6 It can used as nutrient preparations, drug 
reservoirs, or templates for the preparation of microspheres, 
nanoparticles and silicates microstructures.4,7-9 This review 
offers the role of physical properties in the development of 
non- aqueous emulsions.  The evaluation and application of 
non-aqueous emulsion are also mentioned.  
  
Role of physical properties in the 
development of non-aqueous emulsions 
  
For development of the non-aqueous emulsions, there are 
the crucial factors that should be considered as following:  
 
1. Critical micelle concentration 
Typically, the surfactant molecules at low concentration 
disperses as monomer in solution because the entropy of 
mixing overweighs the attractive forces operating between the 
surfactant molecules. When the concentration of surfactant is 
increased, they can spontaneously aggregate into 
thermodynamically stable structure, which was occurred over 
a narrow range of concentration:  the critical micelle 
concentration (CMC). Below CMC, surface-active agents are 
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preferentially adsorbed mainly at air-  polar solvent interface 
as monomer. When surfactant monomers encounter the polar 
solvent environment, polar solvent molecules repel the polar-
solvent insoluble hydrocarbon tail of amphiphiles.  Therefore, 
the hydrophobic tails are directed away from polar- solvent, 
while the solvophillic heads are attracted by polar solvent by 
electrostatic attraction force. As the concentration of surfactant 
increases, the interface and the bulk phase become saturate 
with monomer.10   
 
2. Particle size 
As the globule size is reduced, they tend to exhibit 
Brownian movement. The diameter of globule is considered a 
major factor, which causes creaming of microemulsions.  In 
general, the rate of creaming decreases fourfold when the 
globule diameter is halved.  In microemulsions, the rate of 
creaming is insignificant; however, it is necessary to choose 
optimum globule size for maximum stability.10 
 
3. Viscosity 
Viscosity is a common strategy for the stability of an 
emulsion.  As the viscosity increases, flocculation of globules 
is reduced because the Brownian movement of a globule is 
restricted.  This decrease of mobility of globules eventually 
leads to creaming. Due to this undesirable effect, an optimum 
viscosity must be achieved for good stability.10 The stability of 
the non-aqueous emulsion can be enhanced by increasing the 
viscosity of the continuous phase. For the castor oil in silicone-
oil emulsions, the viscosity of the silicone continuous phase 
was varied from 1 to 100 centipoises.  With a non- ionic 
surfactant as the emulsifier, the optimal viscosity was found to 
be 48 centipoise.  It is evident that there should be such an 
optimum as the energy required to produce small droplets is 
greater in liquids of the higher viscosity.  On contrary, a 
continuous phase having a lower viscosity has a chance to 
cause creaming or settling of the emulsion.11 
However, the viscosity of the emulsion should also be 
considered for the ease of injection to reduce the pain and 
provide patient compliance, especially in the injectable non-
aqueous emulsion system of ISM.  The presence of oil in the 
external phase may have an effect on the viscosity of the 
system. The previous study revealed that the trend of viscosity 
of ISM was similar with ISG but the viscosity of ISM was lower 
because of the presence of oil in the external phase12,13 that 
promoted the higher syringeability and to be easily 
administered. In addition, the hindrance effect of the oil phase 
affecting the ISM system.13 
 
4. Physical properties of an interface 
Emulsion systems have minimal thermodynamic stability, 
thus, it tends to phase- separate whereas the primary driving 
force for that is the droplet interfacial free energy.  When a 
surfactant is added, it concentrates at the two immiscible 
interfaces that imparts a degree of stability by lowering the 
interfacial tension.  Moreover, it prevents immediate droplet 
recoalescence during preparation.14 Therefore, the interfacial 
film of the emulsifier is essential for the stability of the product. 
The film should be sufficiently elastic and form rapidly as soon 
as droplets are produced, which facilitates the production of 
microemulsion.  Suitable emulsifying agents such as 
surfactants should be selected. The physical properties of an 
interface also depend on the pH of the preparation. Therefore, 
optimum pH has to be maintained for maximum stability.10 
 
Evaluations of non-aqueous 
emulsion 
1. In-vitro drug release  
One of the most common methods used in the study of in 
vitro drug release utilizes a modified diffusion apparatus with 
dialysis membrane such as drug release study of cytarabine 
implants.15 The formulations were placed into conical vials 
open on one side and closed with dialysis membrane on other 
side and submerged in phosphate buffers pH 7. 4 at 37ºC.15 
Equal volume of fresh media was replaced to maintain the 
total volume.  Another example was a study of lipophilic drug 
substances such as H- dexamethasone and H-
dehydroepiandrosterone ( DHEA)  solubilized in castor oil 
phase and emulsions with different phase volumes were 
prepared using silicone oil.  Each formulation was dialyzed 
against 100 ml of purified water using a snakeskin dialysis 
tubing with continual stirring.  One hundred microliters of 
dialysis media was withdrawn at predefined intervals and 
radioactivity was measured. Sink conditions were maintained 
throughout the experiment. The equivalent volume of medium 
was replaced after each sampling procedure.11 
 
2. Stability test 
The stability study of emulsions was performed by 
observing the creaming and breaking behavior over time. The 
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stability criterion used was the time until breaking: i.e. the time 
after which 5%  of the total amount of oil was floating on the 
emulsion. 16,17 The physical and chemical stability study of 
griseofulvin non- aqueous nanoemulsion are evaluated by 
agitation test, centrifugation test, freeze- thaw cycles and 
amount of drug content using UV-visible spectrophotometer.18 
Typically, the visual observation is the method to analyze the 
emulsion stability. It can be studied by placing the emulsion in 
tubes and then stored in ambient conditions.  The separation 
of another phase at the bottom of the container or a complete 
breakdown into two phases with a layer of surfactant between 
them is the sign of destabilization.14  
The physical stability of non- aqueous in situ PLGA 
microparticles emulsion was determined by measuring the oil 
separation as a function of time.  In order to screen potential 
stabilizer with optimized ratio, formulations were stored 
vertically in 1 ml syringes in a desiccator under ambient 
conditions.19 In process of separation, the oil phase had arisen 
upward where the solvent moved downward and the rate of 
solvent separation from the oil phase was calculated. Another 
example is the assessment of physical and chemical stability 
of the in situ implants.  Stability studies were conducted over 
the course of 1 month under various storage conditions 
according to ICH guidelines.  Samples containing optimized 
formulations were placed in vials and stored at 40ºC/75%RH. 
After 90 days the formulations were inspected for physical 
appearance and drug content.15 
 
3. Interfacial tension 
Interfacial tension is used for the evaluation of the role of 
surfactants on emulsion systems and interaction behavior 
between dispersed and continuous phases. The pendant drop 
method is used by a large number of researches in the 
determination of interfacial tension.  Castor oil containing 5% 
w/w of each surfactant was slowly formed as a drop in silicone 
oil at 20ºC. The dimensions of each drop were obtained from 
digital photographs.  De, the equatorial diameter, and Ds, the 
diameter at the plane at a distance De from the tip of drop 
were measured.  Using the tables reported by Adamson 
( 1990) 20, the correlation factor ( H)  from the shape factor 
(S=Ds/De) was obtained. Interfacial tension (γ) was calculated 
from the following equation.  
γ= (�p g De2)/H 
Where �p is density difference between the phases and 
g is gravitation constant.  The method was validated by 
determining interfacial tension between n- hexane and 
water.4,11 
Another method for the evaluation of surface tension is 
using the micropipette tensiometry to measure the interfacial 
tension for individual emulsion droplets containing amphiphillic 
block copolymers during solvent evaporation.21 
 
4. Pseudo-ternary phase diagram 
The emulsification behavior of non- aqueous emulsion 
systems is completely unpredictable and conventional theories 
of emulsification and HLB system cannot be applied. Pseudo-
ternary phase diagram can be used to facilitate the 
optimization of non-aqueous emulsions. The pseudo–ternary 
phase diagram was constructed using titration.10  
 
5. Emulsion droplet size 
The diameter of globules is critical factor for creaming of 
non- aqueous emulsions.  Emulsion droplet sizes were 
investigated by Beckman Coulter counter based on the laser 
diffraction phenomenon.10 The particle size and size 
distribution were evaluated by laser diffraction measurements 
and investigated the droplet sizes of the ISM-emulsions under 
an optical microscope.5 The suitable emulsifier should be able 
to film at the interface between dispersed and continuous 
phase.  The emulsion droplets interface was assessed by 
determining hot- stage polarized light microscopy, cryo-
scanning electron microscopy (Cryo-SEM) and freeze etching-
transmission electron microscopy (FE-TEM).19 
 
6. Rheological study viscosity measurement 
The flow behavior and viscosity of the non- aqueous 
emulsions were investigated using a controlled stress mode 
of the plate and cone device connected with computer 
interface of a rheometer.22 
 
Application in pharmaceuticals 
Non-aqueous emulsions are well known as the solvent for 
drugs, suspension vehicles, oleogels, soft gelatin or 
magnoresponsive drug delivery system.  It provides potential 
vehicles for lipophilic drugs.  Detail of each system is as 
follows: 
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1. Oral delivery 
Biopharmaceutical classification system ( BCS)  is a 
guideline issued by the USFDA, which classified drug 
substances into different classes based on the three 
fundamental properties which affect the bioavailability of oral 
preparations: dissolution, solubility and intestinal permeability. 
According to BCS, drug substances which have a high 
permeability, low solubility (BCS class II) and low permeability, 
low solubility ( BCS class IV)  are poorly soluble in 
gastrointestinal fluid. Non-aqueous microemulsions, acting as 
the super solvent for poorly soluble drugs, can enhance the 
solubilization of these drugs and overcome the dissolution-
related bioavailability problems.7,10 A rutin- loaded non-
aqueous self- double- emulsifying delivery system ( SDEDS) 
was stabilized by glycerol monostearate and nonionic 
surfactants. The non-aqueous SDEDS spontaneously formed 
into oil- in- oil- in- water ( O/ O/ W)  double emulsions in the 
gastrointestinal environment and improve rutin 
bioavailability.23 
 
2. Topical drug delivery 
The stable non- aqueous microemulsion comprising 
glycerin and mineral oil stabilized by glycerol monosterate with 
cosurfactant could enhance the dermal penetration/ 
permeation of griseofulvin and drug stability.24 The use of 
hydrophobic surfactants was more efficient than hydrophilic 
surfactant.  The emulsion exhibited antifungal activity against 
Microsporum gypsum with no significant sign of skin irritation 
on mice skin.  Other compounds both hydrophilic ( 5-
fluorouracil, apomorphine hydrochloride, diphenhydramine 
hydrochloride, tetracaine hydrochloride, methotrexate)  and 
lipophilic drugs ( estradiol, finasteride, ketoprofen, meloxicam, 
felodipine, triptolide)  have reported to be loaded in non-
aqueous microemulsion for enhancing their skin permeation.10 
Non- aqueous microemulsion improved the delivery of 
progesterone, α- tocopherol, and lycopene into viable skin 
layers.25 Non- aqueous self- double- emulsifying drug delivery 
systems ( SDEDDS)  prepared by mixing the hydrophilic 
surfactants and oil in oil emulsion could increase aqueous 
solubility of trans-reveratrol and improve its skin retention.26 
 
3. Protein and peptide drug delivery 
Designing oral peptides and protein delivery systems has 
been a persistent challenge to pharmaceutical scientists due 
to their several unfavorable physicochemical properties 
including large molecular size, susceptibility to enzymatic 
degradation, short plasma half- life, ion permeability, 
immunogenicity, and the tendency to undergo aggregation, 
adsorption, and denaturation.27,28 However, numerous 
peptides and proteins are identified as novel therapeutic 
drugs. To circumvent this, non-aqueous microemulsions have 
been developed and patented for the oral delivery of protein 
and peptide drugs.10 Emulsions dosage forms can protect the 
protein and peptide from chemical and enzymatic breakdown 
in the intestinal lumen and increase the drug absorption which 
is dependent on the type of emulsifying agent, particle size of 
the dispersed phase, pH, solubility of drug, type of lipid phase, 
etc.29 The lipid phase of microemulsions comprising medium 
chain fatty acids triglycerides increased the bioavailability of 
muramyl dipeptide analog.30 
 
4. Magnetic system 
The flow of droplets of magnetite nanoparticles in the 
capillaries can be controlled by designing the magnetite 
nanoparticles into oil- in-oil emulsion.  This feature has drawn 
much interest especially for the design of microfluidic and 
pulsatile drug release systems.  Application of magneto-  and 
electrorheological systems to achieve a controllable delivery 
device is an area of research which is gaining interest.7,10,31  
 
5. Controlled release vehicle 
Novel non- aqueous emulsions have the potential to be 
used as a controlled release system for lipophilic drugs.  In 
addition, the non- aqueous emulsion provides spontaneous 
formation, ease of manufacturing and scale- up, 
thermodynamic stability, improved drug solubilization of 
hydrophobic drugs and bioavailability.  Therefore, these 
systems have emerged as the novel vehicles for controlled 
released drug delivery for percutaneous, oral, topical, 
transdermal, ocular and parenteral administration of 
medicaments.10 The increased local systemic delivery of non-
aqueous microemulsions through the skin makes them the 
suitable vehicles for the delivery of antifungal agents.  The 
intramuscular absorption of this anhydrous microemulsion 
offers some advantages as the depot or reservoir vehicles for 
lipophilic drugs in controlled delivery systems.10 The release 
profile of dehydroepiandrosterone ( DHEA) , a highly lipophilic 
molecule, added to the internal phase of emulsion follows first-
order release kinetics.3 The controlled parenteral drug delivery 
of novel in situ forming microparticles emulsion has been 
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reported.32 The polymer in the internal phase of ISM emulsion, 
when contacts with aqueous physiological fluid, forms a depot 
like matrix by exchange of polar solvents in the emulsion with 
physiological fluid and subsequently the drug released from 
this depot in a controlled manner. The drug released from the 
ISM system decreased when the polymer concentration was 
increased or the polymer phase: external oil phase ratio was 
increased.  Thus, the type of biocompatible polar solvent 
affected the drug release.32 The six months prolonged 
leuprolide ISM could be developed by blending poly( lactide-
co-glycolide) with different molecular weights.33 ISM is suitable 
for achieving new implant delivery system with low risk of 
dose-dumping, capable of being modulated to exhibit varying 
release patterns, reproducible, easily applicable and well 
tolerated compared with classically surgical implants which 
Risperidone-ISM™showed a possibility for prolonged release 
with intramuscular injection.34 
 
6. Capsules 
Regarding the approximately 40% of new chemical entities 
that are hydrophobic in nature, the delivery of poorly water-
soluble drugs has been the subject of much research.  One 
area in which published literature is lacking is in the field of 
non-aqueous emulsions filled into capsules. The polyethylene 
glycol ( PEG)  has been used as a continuous phase in the 
preparation of such emulsion.35-37 The emulsion comprising 
low solubility bioactive agents can be filled into hard gelatin 
as well as soft gelatin capsules.  These liquid systems, when 
administered, subsequently result in the formation of a fine 
emulsion in the gastric fluid.6 This process favors the 
bioavailability of lipophilic drugs or helps to avoid a mucosal 
irritation which can be caused by high concentration of 
administrated drugs.  The non- aqueous emulsion is inert 
toward the capsule shells and did not compromise the seal of 
these systems over an extended period of time.7,10 
 
7. Periodontal delivery  
Aggressive periodontitis, by definition, causes rapid 
destruction of the periodontal attachment apparatus and the 
supporting alveolar bone.38 It is a major cause of tooth loss. 
The non- aqueous in situ forming microparticles for treatment 
of periodontitis provides the advantages of easier injectability 
through smaller needle sizes.22 improved muscle compatibility 
observed in Sprague Dawley rats39,40 and decreased initial 
burst release of low molecular drugs and peptides in vitro and 
in vivo.5,32,39,41 
Bleached shellac dissolved in biocompatible solvents 
including N-methyl pyrrolidone (NMP), dimethyl sulphoxide 
(DMSO) and 2- pyrrolidone was employed as the internal 
phase of non-aqueous emulsion using olive oil emulsified with 
glyceryl monostearate ( GMS)  as the external phase of in 
ISM.12,13,39,42 For periodontitis treatment this doxycycline 
hyclate- loaded bleached shellac ISM exhibited pseudoplastic 
flow and notably low injectability force.13,42 The transformation 
from emulsion into microparticles of ISM prepared with 2-
pyrrolidone was slow due to slower phase inversion which 
provoked less porous topography of bleached shellac matrix 
microparticles. This developed ISM attained a prolonged drug 
release for 47 days with Fickian diffusion and markedly 
inhibited P. gingivalis, S. mutans and S. aureus thus it was a 
suitable formulation for periodontitis treatment.12,13,42 
 
8. Cosmetic preparation 
Emulsions comprising organosilicon material are useful in 
a vast variety of applications and they are primarily intended 
for personal care usage.43 This non- aqueous emulsion 
intended for cosmetics can be used alone or in combination 
with cosmetic ingredients. There are a wide variety of uses as 
cosmetic preparation such as the carriers for antiperspirants 
and deodorants.  It can be used as the lubricant and can 
improve the desired properties in skin creams, skin care 
lotions, moisturizers, facial treatments such as acne or wrinkle 
removers, personal and facial cleansers, bath oils, perfumes, 
colognes, sunscreens, pre- shave and after- shave lotions, 
liquid soaps, shaving soaps, and shaving lathers.  They can 
be used in hair shampoos, hair conditioners, hair sprays, 
mousses, permanents, depilatories, and cuticle coats. 
Emulsions can also function as leveling and spreading agents 
for pigments in make- up color cosmetics, foundations, 
blushes, lipsticks, lip balms, eyeliners, mascaras, oil 
removers, color cosmetic removers, and powders.  When 
incorporated into sticks, gels, lotions, aerosols, and roll- ons, 




Emulsions are also capable of functioning as carriers for 
pharmaceuticals, biocides, herbicides, pesticides, and other 
biologically active substances.  For further use, they can be 
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used as additives for cellulosic or synthetic nonwoven carrier 
substrates used in wet-like cleansing wipes such as wet-wipe 
tissues, and towels, marketed generally for personal hygiene 
and household cleaning tasks.7,10 
The consideration of components used in non- aqueous 
emulsion should be conducted.  The important factor is that 
the choice of suitable organic polar solvents considering their 
toxic potential or requirements of newly synthesized 
emulsifiers that will not comprise the high irritating to the 
gastrointestinal mucous but exhibit the tissue compatibility. 
The Food and Drug Administration (FDA)  gave approval for 
poly (dl- lactide) , lactide/ glycolide copolymers, and 
lactide/caprolactone copolymers because of their degradation 
characteristics.45 The used organic solvent should have its 
solvating ability and its safety/toxicology profile.46 
 
Conclusion 
Critical micelle concentration, particle size, viscosity and 
interface of two phases are physical properties that should be 
considered in the development of the non-aqueous emulsions. 
In the pharmaceutical field, this system is developed as the 
vehicle for hydrophobic drugs or drug susceptible to 
hydrolysis.  Moreover, such systems allow the sustained or 
controlled release manners.  Non- aqueous emulsions have 
been used for oral and topical drug delivery, protein and 
peptide drug delivery, periodontal pocket delivery and 
cosmetic application.  Moreover, these systems also have 
been filled in capsule or used as carrier for magnetite 
nanoparticles and prepared as the multiple emulsion.  Thus, 
the non- aqueous emulsions have possessed as the potential 
tool for pharmaceutical applications. 
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